ふやい

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Complete if Known					
Application Number	10/635,428				
Filing Date	August 6, 2003				
First Named Inventor	Balaji Venkataraman				
Art Unit	1615				
Examiner Name	Thurman K. Page				
Attorney Docket Number	52761-0100 (285976)				

	U.S. PATENT DOCUMENTS								
Examiner	Cito	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Pages Columns Lines Where Relevant				
Initials *	Cite No.	Number - Kind Code ² (if known)	MM-DD-YYYY	Gleo Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear				
ap	1	US-5,405,613	04-11-1995	Rowland					
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
	· ·	US-							
		US-							
		US-							
		US-							
		US-							
		US-							
		US-							
	Ī	US-							
		US-							

	FOREIGN PATENT DOCUMENTS								
Examiner Cite No.1	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines, Where Relevant					
	Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Passages or Relevant Figures Appear	T ⁶				
									
			-						
			<u> </u>		1				

Examiner Signature	E. Pecle	Date Considered	3/16/05

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. Enter Office that Issued the document, by the two-letter code (WIPO Standard ST.3). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. Applicant is to place a check mark here if English language Translation is attached.

This collection of Information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

52761-0100 (285976)

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
to persons are required to respond to a collection of information unless it contains a valid OMB control number Under the Paperwork R Complete if Known Substitute for Form 1449/A/PTO **Application Number** 10/635,428 **Filing Date** August 6, 2003 INFORMATION! **First Named Inventor** VENKATARAMAN **Group Art Unit** 1615 (use as many sheets **Examiner Name** Unassigned

Attorney Docket Number

U.S. PATENT DOCUMENTS								
Examiner Initials	Cite No.1	U.S. Patent Number	Document Kind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
4	1.	6,369,041		HORROBIN et al.	04-09-2002			
4	2.	5,494,678		PARADISSIS et al.	02-27-1996			
						- M		
			•		-			

Sheet 1

of 1

	FOREIGN PATENT DOCUMENTS									
		Fo	reign Patent Do			Date of Publication of	Pages, Columns, Lines, Where			
Examiner Initials	Cite No.'	Office ³	Number ⁴	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	T⁴		
		+						_		
			 							

Examiner Signature	G. Recla		Date Considered	3116/05	
-----------------------	----------	--	--------------------	---------	--

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Ascot 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO

	(000 00	,	,
1		of 1	

Complete if Known						
Application Number 10/635,428						
Filing Date	August 6, 2003					
First Named Inventor	VENKATARAMAN					
Group Art Unit	1615					
Examiner Name	Unassigned					
Attorney Docket Number	52761-0100 (285976)					

U.S. PATENT DOCUMENTS							
Cite	U.S. Patent			Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear		
1.	6,040,333		JACKSON	03-21-2000			
			,				
							
							
	1						
	 			· · · · · · · · · · · · · · · · · · ·			
+ <u>.</u>	<u> </u>						
	<u></u>				······································		
		· · · · · ·		+			
							
	Cite No.1	Cite No.¹ Number	U.S. Patent Document Cite Kind Code ² No. ¹ Number (if known)	Cite No.1 Number (if known) Name of Patentee or Applicant of Cited Document	U.S. Patent Document Kind Code* Number (if known) 1. 6,040,333 JACKSON Date of Publication of Cited Document MM-DD-YYYY ACKSON 03-21-2000		

	FOREIGN PATENT DOCUMENTS										
	•	Fo	reign Patent Do			Date of Publication of	Pages, Columns, Lines, Where				
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code ³ (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevant Figures Appear	Τ ⁶			
		+									
		 									
		· .									
	<u> </u>	 						<u> </u>			
	<u> </u>	+						├			
		+	· - · · · · · · · · · · · · · · · · · ·					-			
		+									
	 	1-1-									

Examiner Signature	E. Peele	Date Considered	3/16/00
		Considered	

¹Unique citation designation number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language translation is attached.

Under the Processor Reduction Act of 1995, no persons are required to responsive a Substitute for Form 1449/A/PTO

INFORMATION DISCLOSURE Filling Dat First Nam

Group Art U

(use as many sheets as necessary

of 6

(Abstract)

Sheet 1

Approved for use through 10/31/2002 OMB 0651-0031

Approved for use through 10/31/2002 OMB 0651-0031

Approved for use through 10/31/2002 OMB 0651-0031

Page 1 1 2003

Approved for use through 10/31/2002 OMB 0651-0031

	plete if Kn wn	
Applicati n Numb r	10/635,428	
Filing Dat	August 6, 2003	
First Nam d Inv ntor	Venkataraman	
Group Art Unit		
Examiner Name	, , , , , , , , , , , , , , , , , , , ,	
Attorney Docket Number	52761/295076	

				U.S. PATENT DOCUMENT	S	
		U.S. Patent Docum			Date of Publication of	Pp., Columns, Lines, Where
Examiner initials	Cite No. ¹	Number	(ind Code ² (if known)	Name of Patentee or Applicant of Cited Document	Cited Document MM-DD-YYYY	Relevant Passages or Relevan Figures Appear
4	1.	5,494,678		Paradissis, et al.	02-27-1996	
ij	2.	5,563,126		Allen, et al.	10-08-1996	
9	3.	5,795,873		Allen	08-18-1998	
4	4.	5,801,161		Merkus	09-01-1998	
Ċ	5.	5,932,624		Herbert	08-03-1999	
Ġ	6.	5,962,048		Register	10-05-1999	
4	7.	6,039,978		Bangs, et al.	03-21-2000	
Śp	8.	6,048,846		Cochran	04-11-2000	
4	9.	6,121,249		Weissman. et al.	09-19-2000	
4	10.	6,127,370		Smith, et al.	10-03-2000	
4	11.	6,207,651	B1	Allen, et al.	03-27-2001	
4	12.	6,299,896	B1	Cooper, et al.	10-09-2001	
Sp	13.	6,323,188	B1	Weissman	11-27-2001	
4	14.	6,361,800	B1	Cooper, et al.	03-26-2002	
Ġ,	15.	6,369,041	B2	Horrobin, et al.	04-09-2002	
ζ,	16.	6,479,545	B1	Levinson, et al.	11/12-2002	
Ġ	17.	6,528,496	B1	Allen, et al.	03-04-2003	
ie	18.	2002/001014	8 A1	Horrobin, et al.	01-24-2002	
4	19.	2002/013671	1 A1	Cochran	09-26-2002	
ما	20.	2002/014646	3 A1	Clayton	10-10-2002	
4	21.	2003/004935	2 A1	Mehansho, et al.	03-13-2003	
6.	22.	2003/017136	A1	Cruz, et al.	01-23-2003	

				FORE	IGN PATENT DOCUMENTS			
			Foreign Patent Docume	ent		Date of Publication	Pp., Columns, Lines,	Т
Examiner Initials	Cite No.1	Office ³	Number ⁴	Kind Code ⁵ (if known)	Name of Patentee or Applicant of Cited Document	of Cited Document MM-DD-YYYY	Where Relevant Passages or Relevant Figures Appear	⊤º
Sp	23.	EP	0366480 (Abstract)	B1	Bar Ilan University	08-24-1994		
4	24.	wo	96/11009 (Abstract)	A1	UK	04-18-1996		
80	25.	wo	98/01157 (Abstract)	A1	WWK Trust, Worsley, Andrew Peter	01-15-1998		-
8	26.	wo	2000/056295 (Abstract)	A2	Kilgowan Limited	09-28-2000		
y	27.	wo	2001/056609 (Abstract)	A1	Germany	08-09-2001		
8	28.	wo	2002/087593 (Abstract)	A1	Cobalz Limited	11-07-2002		

Examiner	G Recle	Date	3/16/05
Signature	. new	Considered	

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent document, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

ATLUB02 138545.2

PTO/SB/08A (08-00)
Approved for use through 10/31/2002 OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE collection of information unless it contains a valid OMB control number PADENTA Complete if Kn wn Substitute for Form 1449/A/PTO Applicati n Number 10/635,428 Filing Dat August 6, 2003 **INFORMATION DISCLOSURE** First Nam d Invent r Venkataraman STATEMENT BY APPLICANT **Group Art Unit** (use as many sheets as necessary **Examiner Name** Sheet 2 of 6 **Attorney Docket Number** 52761/285976

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	29.	ALTURA, BURTON M. and ALTURA, BELLA T., "Magnesium and Cardiovascular Biology: An	
4		Important Link Between Cardiovascular Risk Factors and Atherogenesis," Cellular and Molecular	
•		Biology Research, 1995, pp. 347-359, Vol. 41, No. 5.	
	30.	ANDERSSON, H.C., et al., "Long-Term Outcome in Treated Combined Methylmalonic Acidemia	<u> </u>
4		and Homocystinemia," Genet Med, May-June 1999, pp. 146-150. (Abstract)	
	31.	APPEL, LAWRENCE, J., et al., "A Clinical Trial of the Effects of Dietary Patterns on Blood	
4		Pressure," N. Engl. J. Med, April 17, 1997, pp. 1117-1124, Vol. 336, No. 16.	
	32.	BASU, TAPAN K. and MANN, SARABJIT, "Vitamin B-6 Normalizes the Altered Sulfur Amino Acid	
4	!	Status of Rats Fed Diets Containing Pharmacological Levels of Niacin Without Reducing Niacin's	
,		Hypolipidemic Effects," J. Nutr., 1997, pp.117-121, Vol. 127.	1
1	33.	BLOOM, O. JOSH, et al., "Do Antioxidants (Vitamins C, E) Improve Outcomes in Patients With	
5		Coronary Artery Disease?" J. Fam. Prac., November 2002, p. 978, Vol. 51, No. 11.	
_	34.	BLUMBERG, A., et al., "Vitamin Nutrition in Patients on Continuous Ambulatory Peritoneal	
4		Dialysis (CAPD)," Clin Nephrol, November 1983, pp. 244-250, Vol. 20, No. 5. (Abstract)	
	35.	BOUSHEY, CAROL J., et al., "A Quantitative Assessment of Plasma Homocysteine as a Risk	
V		Factor for Vascular Disease," JAMA, October 4, 1995, pp. 1049-1057, Vol. 274, No. 13.	
4	36.	BRATTSTROM, L. E., et al., "Folic Acid - An Innocuous Means to Reduce Plasma	T
4		Homocysteine," Scand J. Clin. Lab Invest., 1998, pp. 215-221, Vol. 48.	
	37.	BRATTSTROM, LARS E., et al., "Folic Acid Responsive Postmenopausal Homocysteinemia,	
4		Metabolism," November 1985, pp. 1073-1077, Vol. 34, No. 11.	
	38.	BRATTSTROM, LARS, et al., "Impaired Homocysteine Metabolism in Early-Onset Cerebral and	
4		Peripheral Occlusive Arterial Disease," Atherosclerosis, 1990, pp. 51-60, Vol. 81.	
	39.	CAMPBELL, BRUCE G., et al., "Do Calcium Supplements Prevent Postmenopausal Osteoporotic	
۵		Fractures?" J of Fam Prac., March 2003, pp. 236-237, Vol. 52, No. 3.	
4	40.	CHAMBERS, JOHN C., et al., "Improved Vascular Endothelial Function After Oral B Vitamins,"	1
'		Circulation, Nov. 14, 2000, pp. 2479-2483, Vol. 102.	

Concidered	Examiner Signature	4. Rech	Date Considered	31/6/25
------------	-----------------------	---------	--------------------	---------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE to a collection of information unless it contains a valid OMB control number Application Number Complete if Known Substitute for Form 1449/A/PTO 10/635,428 Filing Dat August 6, 2003 **INFORMATION DISCLOSURE** First Nam d Inv ntor V nkataraman STATEMENT BY APPLICANT **Group Art Unit** (use as many sheets as necessary **Examiner Name** 3 of 6 **Attorney Docket Number** 52761/285976

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	41.	CHAN, P., et al., "Randomized, Double-Blind, Placebo-Controled Study of the Safety and Efficacy	
3		of Vitamin B Complex in the Treatment of Nocturnal Leg Cramps in Elderly Patients with	
γ		Hypertension," J Clin Pharmacol., 1998, pp. 1151-1154, Vol. 38, No. 12. (Abstract)	
	42.	DOSHI, SAGAR N., et al., "Folic Acid Improves Endothelial Function in Coronary Artery Disease	
4		via Mechanisms Largely Independent of Homocysteine Lowering," Circulation, January 1/8, 2002,	1
′		pp. 23-26, Vol. 102.	
	43.	DUDMAN, NICHOLAS P. B., et al., "Homocysteinemia: Depressed Plasma Serine Levels,"	\dagger
4		Metabolism, February 1987, pp. 198-201, Vol. 36, No. 2.	
	44.	ELIAN, et al., "Hydroxocobalamin Reduces Hyperhomocysteinemia in End-Stage Renal Disease,"	1
4		Metabolism, July 2002, pp. 881-886, Vol. 51. (Abstract)	} }
	45.	FANG, JAMES C., et al., "Effect of Vitamins C and E on Progression of Transplant-Associated	\dagger
5,		Arteriosclerosis: A Randomised Trial," The Lancet, March 30, 2002, pp. 1108-1113, Vol. 359.	
	46.	FRANKEN, D.G., et al., "Effect of Various Regimens of Vitamin B ₆ , and Folic Acid on Mild	1
9		Hyperhomocysteinaemia in Vascular Patients," J. Inher. Metab. Dis., 1994, pp. 159-162, Vol. 17.	
	47.	GABY, A. R., "Intravenous Nutrient Therapy: The Myers' Cocktail," Altern Med Rev, Oct. 2002,	
4		pp. 389-403.	
7	48.	GARG, REKKA, et al., "Niacin Treatment Increases Plasma Homocyst(e)ine Levels," Am Heart J.,	
4		December 1999, pp 1082-1087, Vol. 138, No.6, Part 1.	1 1
	49.	GOTTFRIES, C. G., "Pharmacological Treatment Strategies in Alzheimer Type Dementia," Eur	\Box
4		Neuropsychopharmacol, Nov. 1990, pp. 1-5. (Abstract)	
_	50.	HAIDARI, MEHRAN, et al., "Enhanced Susceptibility to Oxidation and Diminished Vitamin E	1
5		Content of LDL from Patients with Stable Coronary Artery Disease," Clinical Chemistry, 2001, pp.	
		1234-1240, Vol. 47, No.7.	
	51.	HARPEY, JEAN-PAUL, et al., "Homocystinuria Caused by 5,10-Methylenetetrahydrofolate	$\vdash \vdash$
4		Reductase Deficiency: A Case in an Infant Responding to Methionine, Folinic Acid, Pyridoxine,	
1		and Vitamin B ₁₂ Therapy," J Pediatrics, February 1981, pp. 275-278, Vol. 98, No. 2.] [

			
Examiner Signature	Su Rec C.	Date Considered	8/16/05

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Approved for use through 10/31/2002 OMB 0651-0031

Approved for use through 10/31/2002 OMB 0651-0031

S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE equired to respect to a collection of information unless it contains a valid OMB control number Complete if Known Substitute for Form 1449/A/PTO Application Numb r 10/635,428 August 6, 2003 Filing Dat **INFORMATION DISCLOSURE** First Nam d Inv ntor Venkataraman STATEMENT BY APPLICANT **Group Art Unit** (use as many sheets as necessary **Examiner Name** of 6 **Attorney Docket Number** 52761/285976

		OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS	
Examine r Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
j	52.	HEINECKE, JAY W., "Is the Emperor Wearing Clothes?" Arterioscler Thromb Vasc Biol., August	
5		2001, pp. 1261-1264, Vol. 21.	
	53.	HEINONEN, O.P., et al., "The Effect of Vitamin E and Beta Carotene on the Incidence of Lung	
4		Cancer and Other Cancers in Male Smokers," TN Engl J Med, April 14, 1994, pp. 1029-1035, Vol.	
1		330, No. 15.	
	54.	HENKIN, YAAKOV, et al., "Niacin Revisited: Clinical Observations on an Important But	† –
Υ		Underutilized Drug," Am J Med, September 1991, pp. 239-246, Vol. 91.	
. ,	55.	HERBERT, V., "The Inhibition and Promotion of Cancers by Folic Acid, Vitamin B ₁₂ , and their	<u> </u>
5		Antagonists," American Chemical Society (ACS Symposium series), 1985, pp. 32-36, Vol. 277.	
4	56.	KAUL, NALINI, et al., "α-Tocopherol and Atherosclerosis," E.B.M., 2001, pp. 5-12, Vol. 226.	<u> </u>
	57.	KLERK, M., "Effect of Homocysteine Reduction by B-Vitamin Supplementation on Markers of	
7		Clotting Activation," Thromb Haemost, Aug. 2002, pp. 230-235, Vol. 88.	
	58.	LIAO, FANGZI, et al., "Is Low Magnesium Concentration a Risk Factor For Coronary Heart	
4		Disease? The Atherosclerosis Risk in Communities (ARIC) Study," Am Heart J, September 1998,	
1		pp. 480-490, Vol. 136, No. 3.	
	59.	MARCHESONI, D., et al., "Menopause Rather than Estrogen Modifies Plasma Homocysteine	
4		Levels," International Journal of Gynecology and Obstetrics, 2003, pp. 293-297, Vol. 81.	
4	60.	MASON, JB and MILLER, J.W., "The Effects of Vitamins B12, B6, and Folate on Blood	
7		Homocysteine Levels," Ann NY Acad Sci., Sept. 30, 1992, pp. 197-203.	
	61.	NILSSON, K., et al., "Treatment of Cobalamin Deficiency in Dementia, Evaluated Clinically and	
4		With Cerebral Blood Flow Measurements," Aging (Milano), June 2000, pp. 199-207, Vol. 12.	
	62.	OLSZEWSKI, ANDRZEJ J., et al., "Reduction of Plasma Lipid and Homocysteine Levels by	
4		Pyridoxine, Folate, Cobalamin, Choline, Riboflavin, and Troxerutin in Atherosclerosis,"	
		Atherosclersis, 1989, pp. 1-6, Vol. 75.	
	63.	ROSSI, A., et al., "Early-Onset Combined Methymalonic Aciduria and Homocystinuria:	1
4		Neuroradiologic Findings," Am J. Neuroradiol, March 2001, pp. 554-563, Vol. 22.	

	4 14		
Examiner Signature	G. Recle	Date Considered	3146600

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

. `	Under t	En HI	R P 2000 1 D Reduction Agrical 1995, no	SP 1	∠ y S. Patent and Trader ■ Tr	proved for use through 10/31/2002 OMB 0651-003 mark Office: U.S. DEPARTMENT OF COMMERC
		- O&	25	W.	Com	
Substitute fo	r Form 1449/	APTO VE	عن اعن	10	Application Number	10/635,428
	NEOD		I DICCI OCII	IDE	Filing Dat	August 6, 2003
					First Named Inv nt r	Venkataraman
	Under the Pare-work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Complete if Kn wn Application Number 10/635,428 Filing Dat August 6, 2003					
	((use as many st	neets as necessary		Examiner Name	
Sheet	5	of	6	-	Attorney Docket Number	52761/285976

5	<u> </u>	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	
Examine r Initials	Cite No. ¹	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T
	64.	ROSSOUW, JACQUES E., et al., "Risks and Benefits of Estrogen Plus Progestin in Healthy	
4		Postmenopausal Women" JAMA, July 17, 2002, pp. 321-333, Vol. 288, No. 3.	
	65.	SCHNYDER, GUIDO, et al., "Effect of Homocysteine-Lowering Therapy with Folic Acid, Vitamin	
4		B ₁₂ , and Vitamin B ₆ on Clinical Outcome After Percutaneous Coronary Intervention," JAMA,	
		August 28, 2002, pp. 973-979, Vol. 288, No. 8.	
	66.	SHECHTER, MICHAEL, et al., "Oral Magnesium Supplementation Inhibits Platelet-Dependent	
٦		Thrombosis in Patients With Coronary Artery Disease," Am J Cardio., July 15, 1999, pp. 152-156,	
		Vol. 84.	
	67.	SHECHTER, MICHAEL, et al., "Oral Magnesium Therapy Improves Endothelial Function in	T
4		Patients with Coronary Artery Disease," Circulation, November 7, 2000, pp. 2351-2358, Vol. 102.	
	68.	STABLER, et al., "Elevations of Serum Cystathionine and Homocysteine in Vitamin B-6, Folate	
5		and Cobalamin Deficient Rats," Blood, 1994, pp. 118A, Vol 84, No. 10, Suppl. 1.	
	69.	STAMPER, MEIR J. and MALINOW, M. RENE, "Can Lowering Homocysteine Levels Reduce	T
5		Cardiovascular Risk?" The New England Journal of Medicine, Feb. 2, 1995, pp. 328-329, Vol.	İ
		332, No. 5.	
,	70.	STEIN, JAMES H. and MCBRIDE, PATRICK E., "Hyperhomocysteinemia and Atherosclerotic	T
7		Vascular Disease," Arch Intern Med., June 22, 1998; pp. 1301-1306, Vol. 158.	
	71.	STEPHENS, NIGEL G., et al., "Randomised Controlled Trial of Vitamin E in Patients with	\vdash
5,		Coronary Disease: Cambridge Heart Antioxidant Study (CHAOS)," The Lancet, March 23, 1996,	
		pp. 781-786, Vol. 347.	
4	72.	STIPANUK, MARTHA H., "Metabolism of Sulfur-Containing Amino Acids," Ann. Rev. Nutr., 1986,	T
7/		pp. 179-209, Vol. 6.	
	73.	TICE, JEFFREY A., et al., "Cost-effectiveness of Vitamin Therapy to Lower Plasma Homocysteine	_
_		Levels for the Prevention of Coronary Heart Disease: Effect of Grain Fortification and Beyond,"	
>		JAMA, August 22/29, 2001, pp. 936-943, Vol. 286.	

			
Examiner Signature	h Pech	Date Considered	3/18/20

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Under the Rederivank Reduction	Acjust 1995, no persons are sour	App B. Patent and Traden	PTO/SB/08A (08-00) proved for use through 10/31/2002 OMB 0651-0031 nark Office: U.S. DEPARTMENT OF COMMERCE ation unless it contains a valid OMB control number
RAJEN		RADE! Com	plete if Known
Substitute for Form 1449/A/PTO		Application Number	10/635,428
INCODMATION DIS	CI OCUPE	Filing Dat	August 6, 2003
INFORMATION DIS		First Named Inv ntor	Venkataraman
STATEMENT BY A	PPLICANT	Group Art Unit	
(use as many sheets as n		Examiner Name	
Sheet 6 ds 6		Attorney Docket Number	52761/285976

	SE	P 1 1 2003	
Examine	منا	OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the	Τ.
f Initials	No. C.	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T²
	74.		
/		Disease. Plasma Levels in Healthy Person; During Pathologic Conditions and Drug Therapy,"	
4		Nord Med., 1989, pp. 293-308, Vol. 104, No. 11. (Abstract)] .
,	75.	VALAGUSSA, F., et al., "Dietary Supplementation With N-3 Polyunsaturated Fatty Acids and	
5		Vitamin E After Myocardial Infarction: Results of the GISSI-Prevenzione Trial," The Lancet,	
		August 7, 1999, pp. 447-455, Vol. 354.	
,	76.	VAN DER KUY, et al., "Hydroxocobalamin, A Nitric Oxide Scavenger, In the Prophylaxis of	T
Lp		Migraine: An Open, Pilot Study," Cephalalgia Sept. 2002, pp. 513-519, Vol. 22, No. 7,.	,
	77.	VERHAAR, MARIANNE C., et al., "Effects of Oral Folic Acid Supplementation on Endothelial	
4,		Function in Familial Hypercholesterolemia," Circulation, July 27, 1999, pp. 335-338, Vol. 100.	
,	78.	VIVANCO, N., et al., "Treatment of Anorexia Nervosa," Rev Med Chil, 1992, pp. 69-75, Vol. 120.	† -
7		(Abstract)	
	79.	WATERS, DAVID D., et al., "Effects of Hormone Replacement Therapy and Antioxidant Vitamin	1
4	i	Supplements on Coronary Atherosclerosis in Postmenopausal Women," JAMA, November 20,	
77		2002, pages 2432-3440, Vol 288, No. 19.	
	80.	YANG, CHUN-YUH, "Calcium and Magnesium in Drinking Water and Risk of Death from	
4		Cerebrovascular Disease," Stroke, 1998, pp. 411-414, Vol. 29.	
	 		1 1

			T
Examiner Signature	G. Rech	Date Considered	3/10/08

^{&#}x27;Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

Substitute for